Beam Therapeutics Inc. Common Stock
Here’s whether Beam Therapeutics Inc. Common Stock (BEAM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +19.8%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.83% over 10 days); RSI 21 — oversold; 3-month momentum negative (-7.4%). Currently 34.4% off its 52-week high. Score: -5/7.
BEAM is trading below its 200-day MA ($28.11) — a key warning sign the longer-term trend is under pressure. An RSI of 20.5 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +19.8% compares to +16.5% for SPY (beat the market by 3.3%). The current 34.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.